Related Experiment Video

Updated: Jun 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression

Bruce J Giantonio1

  • 1Abramson Cancer Center of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA. bruce.giantonio@uphs.upenn.edu

Nature Reviews. Clinical Oncology
|June 2, 2009
PubMed

Insights

Targeted therapies like bevacizumab show promise against cancer. Even with resistance to chemotherapy, its antiangiogenic effects may continue, offering a potential therapeutic window.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Conventional chemotherapy faces challenges in overcoming cancer resistance.
  • Targeted therapies represent a promising alternative to traditional treatments.
  • Mechanisms underlying resistance to targeted therapies require further elucidation.

Discussion:

  • The BRiTE study investigated resistance patterns in cancer treatment.
  • Bevacizumab, an antiangiogenic agent, was examined for its persistent effects.
  • Resistance to first-line chemotherapy does not necessarily abrogate bevacizumab's antiangiogenic activity.

Key Insights:

  • Antiangiogenic effects of bevacizumab may persist post-chemotherapy resistance.
  • Understanding resistance mechanisms is crucial for optimizing targeted therapy efficacy.
  • Bevacizumab's sustained action offers potential therapeutic avenues.

Outlook:

  • Further research into bevacizumab's role in resistant cancers is warranted.
  • Exploring combination strategies involving bevacizumab could enhance treatment outcomes.
  • Investigating biomarkers for predicting response to bevacizumab is essential.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...